AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02426762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin sealant
Description: After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
Study NCT02040142 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Study NCT02040142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Study NCT04287322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tactile-kinesthetic stimulation
Description: Tactile-kinesthetic stimulation involved three sessions per day; morning, afternoon, and evening for 10 days starting day 3 of life (initial contact). The stimulation included three phases; Phase 1: With neonates in prone position, moderate pressure was used to provide 12 strokes with palms of the hands, each stroke lasting 5 seconds. The strokes were provided in each area as follows: head, neck, shoulders and back.~Phase 2: In supine position, twelve moderate pressure strokes with palms of the hands, 5 seconds each, were provided in each area as follows:forehead,cheeks,chest, abdomen, upper limbs (each separately), lower limbs, palms and soles.~Phase 3: Kinesthetic stimulation was done for 5 minutes. The intervention comprised five passive flexion and extension movements of each large joint.
Study NCT04287322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recorded maternal voice
Description: Following informed written consent from mothers,maternal voice was recorded (5 minutes talking to her baby and 10 minutes singing) using Philips Electronics, SA2RGA04KS, Netherlands. Recorded voice was played back inside the incubator or cot via micro audio system, which has been validated for safety and feasibility in previous studies (Doheny et al., 2012. Preterm neonate lay in supine/lateral position and recorded maternal voice was played for 15 minutes three times a day (morning, afternoon, evening) starting on day 3 of life up to day 12 of life (10 days).
Study NCT01882257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP
Description: BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
Study NCT01882257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP/AVAPS (Phillips Respironics)
Description: BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
Study NCT05037604 — intervention group
Intervention type: OTHER
Intervention: Physical Examination
Description: Physical Examination made by a dermatologist
Study NCT04065308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Combinations
Description: Daratumumab plus DCEP,combination therapy is administered total of three cycles,every 4weeks(28 days).~Daratumuamb 16mg/kg body weight in 500mL (the first dose,16mg/kg body weight in 1000mL) Weeks 1 to 8: weekly Weeks 9-24 : every 2 weeks if ASCT ineligible or PR but Plasmacytoma response \<CR: every 2 weeks for 12weeks and then every 4 weeks for 8weeks (Total of 8 times, additional administration of daratumumab) if ASCT eligible: From 6 to 12 weeks after ASCT, administration of daratumumab is initiated within 12 weeks of ASCT and twice a month for 12 weeks and then every a months for 8 weeks. (Total of 8 additional administration of daratumumab after ASCT)~1. dexamethasone :40mg/day D1-4, intravenous~2. cyclophosphamide: 400mg/m2 D1-4, intravenous~3. etoposide: 40mg/m2 D1-4, intravenous~4. cisplatin : 7mg/m2 D1-4, intravenous Pegteograstim: 6mg once, SC on day 5 or 6 of each 28-day cycle
Study NCT01408641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
Study NCT01408641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules without topiramate
Study NCT02619851 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALLO-ASC-DFU
Description: Dressing for Second Deep degree Burn injury
Study NCT02619851 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Typical therapy conducted for burn injury patients
Study NCT03303001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial high volume infiltration
Description: This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
Study NCT03303001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial conventional infiltration
Description: This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
Study NCT00963950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transvaginal cholecystectomy
Description: Transvaginal approach to gallbladder removal.
Study NCT00963950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic cholecystectomy
Description: laparoscopic cholecystectomy
Study NCT01893749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CATCH-IT
Description: It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
Study NCT02740309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Brief Behavior Therapy (IBBT) Intervention
Description: The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
Study NCT02740309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Facilitated community referral for mental health treatment
Study NCT04826900 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BoNT-A injections
Description: Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide. The total dose range is 200 units to 500 units. The dose range of each target muscle is as below: 20 and 75 units for flexor carpi ulnaris and flexor carpi radials; 12.5-35 units per fascicle in the flexor digitorum sublimis and flexor digitorum profundus (maximum dose: 120 units for each of these muscles); 10-35 units in the flexor pollicis longus; 25-100 units in the brachioradial ; 50-200 units in the biceps brachii; and 25-75 units in the pronator teres
Study NCT04826900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic therapy (RT)
Description: A wearable robotic hand system will be used in this study. The robotic hand system consisted with a wearable exoskeletal hand, sensor glove, and a control box. On the exoskeletal hand, there are five actuators on each of finger structure that can provide external power to bring individual finger moving. The sensor glove has five sensors that can detect the finger's posture during movement and then manipulates exoskeletal hand via the control box. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeleton hand, and the unaffected hand does the certain transitive and intransitive tasks as the mirror group, and then makes the affected hand do the same movements driven by the exoskeleton robotic hand.
Study NCT04826900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic mirror therapy (RMT)
Description: Wearable robotic hand system and mirror system will be used in this group.. The patients in the group will wear the robotic hand to do the mirror therapy. The patient's unaffected hand wears the sensor glove, the affected hand wears the wearable exoskeletal hand, a mirror box with a mirror will be placed in the patient 's midsagittal plane beside the unaffected hand to block his or her view of the affected hand. The patient's unaffected hand does the certain transitive and intransitive tasks and the patient will be instructed to look at the reflection of the unaffected hand in the mirror as if it is the affected hand (the visual input). At the same time the affected hand will be passively moved by the exoskeleton robotic hand which is under the .control of the unaffected hand.
Study NCT04826900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional task training
Description: After either 45 minutes of RT or RMT, all participants receive 15 minutes of training in functional tasks. The functional tasks included taking up and holding bowl or using eating utensils , bringing a cup for drinking, drying sucks by clips, open ing or closing door , turning on or off the light, cleaning the table or window and so on . The functional tasks training will be bases on the needs and ability of patients.
Study NCT04320836 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical epidural steroid injection
Description: Interlaminar cervical epidural steroid injection with steroid and normal saline at C6-7 and C7-T1 (standard of care).
Study NCT02867306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: Oral
Study NCT02867306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate (MTX)
Description: Oral
Study NCT02867007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK2455
Description: oral dosing
Study NCT02867007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mogamulizumab
Description: i.v. administration
Study NCT02804360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dexamethasone injection
Description: intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
Study NCT02034045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Paramedicine
Study NCT02034045 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Study NCT01921998 — intervention group
Intervention type: PROCEDURE
Intervention: Biomarker and health economics
Description: Biomarkers CK18 and FLT3 Ligand will be collected
Study NCT02663986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational Skills Training (OST) Intervention
Study NCT01605903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Study NCT01605903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
Study NCT03521947 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood picture
Description: Iaboratory investigation
Study NCT03283085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25 mg Ontamalimab
Description: Ontamalimab SC solution for injection
Study NCT03283085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg Ontamalimab
Description: Ontamalimab SC solution for injection
Study NCT00212407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Study NCT02038348 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET with 18F-FDOPA
Study NCT01832740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain stimulation
Description: oscillating direct current brain stimulation
Study NCT01832740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM
Description: no stimulation
Study NCT01731002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.01%
Description: Administered to study eye, once daily (QD) in the evening (PM) for 28 days
Study NCT01731002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-13324 Ophthalmic Solution 0.02%
Description: Administered to study eye, QD in the PM for 28 days
Study NCT01731002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost ophthalmic solution 0.005%
Description: Administered to study eye, QD in the PM for 28 days
Study NCT03461055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender
Description: Lavender aromatherapy
Study NCT03461055 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study NCT03809897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: All participants randomized to varenicline will be titrated to the full dose during the first week and continued up to week 12 following standard dosage. This would be independent of time of discharge, so patients will continue the same treatment after discharge up to complete the 12 weeks.
Study NCT03809897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Patients randomized to nicotine patch will receive 8 weeks of 21mg patch followed by 2 weeks of 14 mg patch and 2 weeks of 7 mg patch.
Study NCT00686543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole will be used for prophylaxis
Study NCT02631720 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Study NCT02631720 — intervention group
Intervention type: PROCEDURE
Intervention: Bronchoscopy
Study NCT01027117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revatio
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
Study NCT01027117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revatio
Description: Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
Study NCT02221609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment based on Movement System Impairment model
Description: The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
Study NCT02221609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General exercise
Description: The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
Study NCT01393093 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study NCT01393093 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Chemoembolization
Description: Transcatheter Arterial Chemoembolization
Study NCT03090906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation palate
Description: Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.~In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick.
Study NCT00448292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX-00023
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Study NCT00448292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for PRX-00023
Description: Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Study NCT00682630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate clinical trial reference tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
Study NCT00682630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyronaridine artesunate to-be-marketed tablets
Description: Single total oral dose of 720:240 mg (4 tablets of 180:60 mg)
Study NCT00924703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAvPAL-PEG
Description: The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Study NCT03040154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)
Study NCT03090906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soft tissue augmentation tuberosity
Description: Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.~Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.~Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.~Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick.
Study NCT03090906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoral optical scan
Description: Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
Study NCT01253590 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire about the use of ECG device
Description: Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
Study NCT00934934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline
Study NCT00934934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anidulafungin
Description: TBA
Study NCT01049607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamp-Crush technique
Description: The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.